These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33851976)

  • 1. Association Between Systemic Corticosteroid Treatment for Cutaneous Immune-Related Adverse Events and Survival Outcomes in Patients With Advanced Cancer.
    Thompson LL; Yoon J; Krasnow NA; Chang MS; Li EB; McMahon DE; Chen ST
    JAMA Dermatol; 2021 Apr; 157(5):599-602. PubMed ID: 33851976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benefit.
    Cho YT; Lin YT; Yang CW; Chu CY
    Sci Rep; 2022 Apr; 12(1):7021. PubMed ID: 35487955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.
    Akturk HK; Couts KL; Baschal EE; Karakus KE; Van Gulick RJ; Turner JA; Pyle L; Robinson WA; Michels AW
    JAMA Netw Open; 2022 Dec; 5(12):e2246400. PubMed ID: 36512357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force "Dermatology for Cancer Patients" International Study.
    Sollena P; Vasiliki N; Kotteas E; Stratigos AJ; Fattore D; Orlandi A; Mannino M; Di Pumpo M; Fida M; Starace M; Apalla Z; Romano MC; Riganti J; Segura S; Martinez AF; Fabbrocini G; Sibaud V; Peris K; On Behalf Of The Eadv Task Force Dermatology For Cancer Patients
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study.
    Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
    medRxiv; 2023 Jan; ():. PubMed ID: 36711758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab.
    Ueda K; Suekane S; Kurose H; Ito N; Ogasawara N; Hiroshige T; Chikui K; Ejima K; Uemura K; Nakiri M; Nishihara K; Igawa T
    Jpn J Clin Oncol; 2022 May; 52(5):479-485. PubMed ID: 35141749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroids for the management of cancer-related fatigue in adults with advanced cancer.
    Sandford A; Haywood A; Rickett K; Good P; Khan S; Foster K; Hardy JR
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD013782. PubMed ID: 36688471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy.
    Duraisamy P; Panicker VV; Jose WM
    Dermatol Pract Concept; 2023 Jul; 13(3):. PubMed ID: 37557151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
    Suo A; Chan Y; Beaulieu C; Kong S; Cheung WY; Monzon JG; Smylie M; Walker J; Morris D; Cheng T
    Oncologist; 2020 May; 25(5):438-446. PubMed ID: 32048768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous adverse events caused by immune checkpoint inhibitors.
    Quach HT; Johnson DB; LeBoeuf NR; Zwerner JP; Dewan AK
    J Am Acad Dermatol; 2021 Oct; 85(4):956-966. PubMed ID: 34332798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Outcomes of Immune-Related Cutaneous Adverse Events.
    Phillips GS; Wu J; Hellmann MD; Postow MA; Rizvi NA; Freites-Martinez A; Chan D; Dusza S; Motzer RJ; Rosenberg JE; Callahan MK; Chapman PB; Geskin L; Lopez AT; Reed VA; Fabbrocini G; Annunziata MC; Kukoyi O; Pabani A; Yang CH; Chung WH; Markova A; Lacouture ME
    J Clin Oncol; 2019 Oct; 37(30):2746-2758. PubMed ID: 31216228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment.
    Wang Y; Yang M; Tao M; Liu P; Kong C; Li H; Chen Y; Yin X; Yan X
    Int Immunopharmacol; 2021 Oct; 99():108031. PubMed ID: 34358857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer.
    Valencia Soto CM; Villacañas Palomares MV; Garcia-Avello Fernández-Cueto A; Barbadillo Villanueva S; Martínez Callejo V; Ochagavía Sufrategui M; Muñoz Cacho P; Valero Domínguez M
    Eur J Hosp Pharm; 2023 Dec; 31(1):40-45. PubMed ID: 35383033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events and clinical outcomes in patients treated with PD-(L)1 blockade for advanced non-small-cell lung cancer.
    Zhang Y; Doran C; Le TK; Dreyfus B; Kola N; Sylvester BE; Lal L; Penrod JR; Meadows Shropshire S
    Future Oncol; 2022 Dec; 18(40):4509-4523. PubMed ID: 36942686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Zhou Y; Chen H; Tang L; Feng Y; Tao Y; Huang L; Lou N; Shi Y
    Immunotherapy; 2023 Feb; 15(3):209-220. PubMed ID: 36710655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous immune-related adverse events from immune checkpoint inhibitor therapy: Moving beyond "maculopapular rash".
    Allais BS; Fay CJ; Kim DY; Semenov YR; LeBoeuf NR
    Immunol Rev; 2023 Sep; 318(1):22-36. PubMed ID: 37583051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis.
    Kraehenbuehl L; Schneider S; Pawlik L; Mangana J; Cheng P; Dummer R; Meier-Schiesser B
    Pharmaceuticals (Basel); 2023 Jun; 16(7):. PubMed ID: 37513847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic adverse events following intraarticular corticosteroid injections for the treatment of juvenile idiopathic arthritis: two patients with dermatologic adverse events and review of the literature.
    Goldzweig O; Carrasco R; Hashkes PJ
    Semin Arthritis Rheum; 2013 Aug; 43(1):71-6. PubMed ID: 23332901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
    Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
    J Am Acad Dermatol; 2023 May; 88(5):1024-1032. PubMed ID: 36736626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the corticosteroid indication and administration route on overall survival and the tumor response after immune checkpoint inhibitor initiation.
    Gaucher L; Adda L; Séjourné A; Joachim C; Chaby G; Poulet C; Liabeuf S; Gras-Champel V; Masmoudi K; Moreira A; Bennis Y; Batteux B
    Ther Adv Med Oncol; 2021; 13():1758835921996656. PubMed ID: 33717227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.